Bioqual (OTCMKTS:BIOQ), Inc. is a privately held contract research organization (CRO) that provides preclinical and translational bioservices to pharmaceutical, biotechnology and academic clients worldwide. The company specializes in in vivo efficacy testing, pharmacology, safety and toxicology assessments, and custom assay development across multiple therapeutic areas, including immunology, oncology, neuroscience and infectious diseases. By combining proprietary animal models with state-of-the-art bioanalytical platforms, Bioqual helps clients advance drug candidates from discovery through IND enabling studies.
Bioqual’s service portfolio encompasses a range of preclinical capabilities, such as humanized and transgenic rodent models, non-human primate studies, immunogenicity and vaccine challenge assays, and cytokine and serology analyses. All studies are performed in compliance with GLP, AAALAC and other regulatory standards, and the company operates integrated vivarium, bioanalytical and pathology laboratories. In addition to standard protocols, Bioqual offers customized study design and biomarker evaluation, supporting both small-molecule and biologic development programs.
Founded in the late 1980s, Bioqual has grown into one of the largest independent CROs in the United States, with headquarters and primary research facilities located in Rockville, Maryland. Over the years, the company has expanded its footprint to serve clients across North America, Europe and Asia-Pacific, forming strategic collaborations with academic centers and contract partners. Bioqual’s emphasis on scientific rigor and regulatory compliance has earned it a reputation for reliability and high-quality data deliverables.
Bioqual’s executive leadership team brings decades of industry experience in biopharmaceutical research and development. The company is led by President and CEO Dr. John T. Smith, whose background includes senior roles in both biotech startups and global pharma CRO divisions. Chief Scientific Officer Dr. Laura M. Chambers oversees study design and scientific strategy, while Chief Operating Officer Michael A. Patterson manages operations, quality assurance and facility expansion. Together, they guide Bioqual’s mission to accelerate therapeutic innovation through tailored preclinical solutions.
